Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic - A retrospective analysis of results in years 1988-2005;Alogenní transplantace krvetvorných buněk u nemocných s chronickou myeloidní leukemií v České republice: Retrospektivní hodnocení výsledků z let 1988 až 2005

Vnitrni Lekarstvi

Volumn 52, Issue 12, 2006, Pages 1172-1180

  Faber, E ^a   Koza, V ^b   Vitek A ^c   Mayer, J ^d   Sedlacek P ^e   Zak P ^f   Zapletalova J ^a   Benesova K ^g   Krejcova H ^g   Steinerova K ^b   Maresova I ^a   Cetkovsky P ^c  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

^c INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^d UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f CHARLES UNIVERSITY   (Czech Republic)

^g CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Allogeneic hematopoietic stem cell transplantation; Chronic myeloid leukemia; EBMT risk score

Indexed keywords

ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DECISION MAKING; DIAGNOSTIC TEST; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; MYELOABLATIVE CONDITIONING; RISK FACTOR; SURVIVAL RATE; TREATMENT PLANNING;

EID: 33845682454     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Registry. Bone Marrow Transplant 1996; 17: S5-S6.
2. Clift RA, Storb R. Marrow transplantation for CML: the Seattle experience. Bone Marrow Transplant 1996; 17: S1-S3.
3. Radich JP, Olavarria E, Apperley JF. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin N Amer 2004; 18: 685-702.
4. Robin M, Guardiola P, Devergie A et al. A 10-year median follow-up study after allogeneic stem cell transplantation for chronic myeloid leukemia in chronic phase from HLA-identical sibling donors. Leukemia 2005; 19: 1613-1620.
5. Goldman JM, Sobocinski KA, Zhang MJ et al. Long-term outcome after allogeneic hematopoietic cell transplantation (HCT) for CML. Biol Blood Marrow Transplant 2006; 12: S17.
6. Crawley C, Szydlo R, Lalancette M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969-2976.
7. Quazilbash MH, Giralt SA, Champlin RE. Nonmyeloablative stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin N Amer 2004; 18: 703-714.
8. Gratwohl A, Baldomero H, Horisberger B et al. Current trends in hematopoietic stem cell transplantation in Europe. Blood 2002; 100: 2374-2386.
9. Simonsson B on behalf of the IRIS (International Randomized IFN vs STI571) Study Group. Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): update from the IRIS study. Blood 2005; 106: 166a.
10. Hahn EA. Glendenning. Quality of life on imatinib. Semin Hematol 2003; 40(Suppl 2): 31-36.
11. Graham SM, Jorgensen HG, Allan E et al. Primitive, quiescent, Philadelphia-positive cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002; 99: 319-325.
12. Baccarani M, Saglio G, Goldman JM et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006 May 18; PMID: 16709930.
13. Hrabánek J, Lukášová M, Vítek A et al. Léčba chronické myeloidní leukemie transplantací kostní dřeně v ÚHKT Praha. Vnitř Lék 1995; 41: 682-687.
14. Vítek A, Cetkovský P, Sajdová J et al. Výsledky transplantací od nepříbuzných dárců u nemocných s CML - I. CP se neliší od výsledků transplantací od HLA-identických sourozenců - zkušenosti jednoho centra. Sborník abstrakt XVIII. Olomouckých hematologických dn̊ 2.-5.6.2004: 10-11.
15. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Lancet 1998; 352: 1087-1092.
16. Borhhäuser M, Kröger N, Schwerdtfeger R et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9-17.
17. Deininger M, Schleuning M, Greinix H et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452-459.
18. Mayer J, Brychtová Y, Doubek M et al. Srovnání reálné ceny léčby chronické myeloidní leukemie nemyeloablativní transplantací krvetvorných buněk s hypotetickou terapií imatinibem (Glivec). Zamyšlení nad velmi drahými medicínskými postupy. Trans Hemat dnes 2006; 12: 6-13.